

Article

# Methodological Variations Affect the Release of VEGF *in Vitro* and Fibrinolysis' Time from Platelet Concentrates

Leonel Alves de Oliveira<sup>1\*</sup>, Tatiana Karla Borges<sup>1</sup>, Renata Oliveira Soares<sup>1</sup>, Marcelo Buzzi<sup>2</sup>; Selma Aparecida Souza Kuckelhaus<sup>1\*</sup>.

<sup>1</sup> Nucleus of Research in Applied Morphology and Immunology, Faculty of Medicine, University of Brasilia, Federal District, Brazil; [profleonel2@gmail.com](mailto:profleonel2@gmail.com); [tatianakarlab@gmail.com](mailto:tatianakarlab@gmail.com); [reosoares@gmail.com](mailto:reosoares@gmail.com); [marcelo.buzzi@gmail.com](mailto:marcelo.buzzi@gmail.com); [selmak@gmail.com](mailto:selmak@gmail.com)

<sup>2</sup> Innovacorium Inc., Gainesville, FL, USA; [marcelo.buzzi@gmail.com](mailto:marcelo.buzzi@gmail.com)

\* Correspondence: [Selma Kuckelhaus \(selmak@gmail.com\)](mailto:Selma Kuckelhaus (selmak@gmail.com))

**Abstract:** Blood Concentrates (BCs) are autologous non-transfusional therapeutical preparations with biological properties applied in tissue regeneration. These BCs differ in the preparation method, in fibrin network architecture, growth factors release as well as in platelet/cell content. Methodological changes result in distinct matrices that can compromise their clinical effectiveness. The present study evaluated the influence of different g-forces and types of tubes in the release of vascular endothelial growth factor (VEGF) from platelet-rich fibrin (PRF) as a function of time. The PRF-like samples were obtained with three g-forces (200, 400, and 800 x g) for 10 minutes in pure glass tubes or in polystyrene-clot activator tubes. Scanning and Transmission electron microscopy was used to morphometric analyzes of PRF's specimens and flow cytometry was used to quantify VEGF slow release until 7 days. Our results showed that platelets were intact and adhered to the fibrin network, emitting pseudopods and in degranulation. The fibrin network was rough and twisted with exosomic granulations impregnated on its surface. An increase in the concentration of VEGF in the PRF supernatant was observed until 7 days for all g forces (200, 400 or 800 x g), with the highest concentrations observed with 200 x g, in both tubes, glass or plastic. Morphological analyzes showed a reduction in the diameter of the PRF fibers after 7 days. Our results showed that g-force interferes with the shape of the fibrin network in the PRF, as well as affect the release of VEGF stored into platelets. This finding may be useful in applying PRF to skin lesions, in which the rapid release of growth factors can favor the tissue repair process. Our observations point to a greater clarification on the methodological variations related to obtaining PRF matrices, as they can generate products with different characteristics and degrees of effectiveness in specific applications.

**Keywords:** fibrin matrix; g-force; growth factors; scanning electron microscopy, fibrinolysis

---

## 1. Introduction

The fibrin matrix is a natural clot that acts as a primordial scaffold for the conduction of tissue repair [1,2]; it is a polymeric three-dimensional network formed after fibrinogen activation by enzymatic peptide cleavage [3]. The polymerization occurs instantly by contact with tissue glycoproteins or by thixotropic oxidation in exogenous mechanisms [4].

The biological basis of hemostasis and tissue repair served for the development of obtaining operational methodologies for non-transfusion therapeutic blood concentrates. These methodologies provide a selective concentration of platelets, mononuclear leukocytes, and glycoproteins in the fibrin

matrix, elements that are directly related to regenerative responses [5]. These blood concentrates have been used in dentistry and medicine as a surgical adjuvant to provide early tissue repair [6,7].

Low-speed centrifugation methods generated blood concentrates enriched with platelets from selective blood separation, and methodological advances have provided platelet-rich fibrin (PRF) from blood samples without anticoagulant, which is characterized by elasticity and mechanical resistance and for concentrating mononuclear leukocytes, glycoproteins and growth factors [8,9].

This topic currently has more than a thousand indexed publications ranging from basic research to clinical evidence [10]. Most scientific articles primarily address its therapeutic potential as a surgical adjuvant in dentistry, such as peri-implantology and maxillofacial surgery [11]. However, new studies in the treatment of chronic wounds and muscle-tendinous lesions in humans introduce the topic in the medical field and constitute a promising therapeutic potential [12-15].

The study of platelet concentrates has been the focus of many basic and clinical studies, with most of them focusing on the therapeutic potential of these aggregates as a surgical adjunct in dentistry, such as peri-implantology and maxillofacial surgery [16-18]. However, its application in the treatment of chronic skin lesions and muscle-tendon injuries in humans has attracted the attention of researchers also in the field of medicine [10,12, 19-21].

The autologous blood concentrates obtained by PRF Standard [22], A-PRF<sup>TM</sup> [23,24], Intraspin L-PRF<sup>TM</sup> [25,26], CGF<sup>TM</sup> [27-30], PRGF<sup>TM</sup> [31,32], Fibrin System<sup>TM</sup> [33], and others [34-39] show methodological variations in centrifugation time, g-force, type of rotor and model of the centrifuge, as well as in the types of tubes for blood collection. All together, these parameters for obtaining platelet concentrates show differences in the organization of the fibrin matrix and in the release kinetics of growth factors [40-42].

Considering that methodological variations may imply the morphological and biochemical characteristics of PRF, the present study aimed to describe the morphology and the influence of g-force on VEGF release up to seven days after its production.

## **2. Materials and Methods**

### **2.1. *Individuals and ethical aspects***

The participants were healthy, non-smoker, adult women (n = 5) who agreed to donate 120 mL of blood to the study. The present study observed all ethical standards for scientific research with humans in conformity with the Declaration of Helsinki (World Medical Association Recommendation 2013). The Research Ethics Committee approved the study of the Medical School of the University of Brasilia under number 055468/2015.

### **2.2. *Obtention of the blood-derived concentrates by peripheral venipuncture and centrifugation.***

In order, blood samples were obtained pure glass tubes type 10 mL (Montserrat, Brazil) and polystyrene clot activator tubes (Greiner Bio-One, Brazil) by vacuum collection. Samples' blood was collected and immediately transferred to 25° rotor fixed-angle centrifuge FibrinFuge25 (Montserrat, Brazil) centrifugated with 200, 400, and 800 x g at 10 minutes.

### **2.3. *Ultrastructural analyses by Scanning Electron Microscopy***

PRF clot's fragment obtained by 200, 400, and 800 x g / 10 minutes were separated and conditioned in plastic tubes free of additives (Greiner Bio-One, Brazil). Immediately after PRF production and after 7, 14 or 21 days at 37 °C, the specimens were sectioned (body, buffy coat and

proximal sediment) and fixed in 2% glutaraldehyde solution and 2% paraformaldehyde in 0.1M sodium cacodylate buffer, pH 7.2. After being fixed, they were washed in 0.1M sodium cacodylate buffer, post-fixed in osmium tetroxide (1%) in sodium cacodylate buffer, then the specimens were dehydrated for 15 minutes in solutions with increasing concentrations of acetone (30 %, 50%, 70%, 90% and 3x 100%). Then, the specimens were dried to the critical point with CO<sub>2</sub> and metalized with gold. For analyzes by scanning electron microscopy (JEOL 7001F, Tokyo, Japan), the images (20 to 20000 x of magnification) were analyzed using GIMP 2.10 software (Cockroach Labs, USA). To the morphometric study we evaluated the diameter of twenty fibers using the digital planimeter of Autocad software (Autodesk, USA).

#### **1.4. Ultrastructural analyses by Transmission Electron Microscopy**

For transmission electron microscopy, analyzes PRF fragments in the buffy coat region were fixed and processed as previously reported. After being impregnated with PolyBed 812 resin (PolySciences, USA) the fragments were sectioned on an ultramicrotome to obtain the images (Jeol 100CXII, Japan). Qualitative analyzes were performed in digital images using the GIMP 2.10 software (Cockroach Labs, USA).

#### **1.5. VEGF Quantification**

The PRF of individuals were maintained up to 7 days at 37 °C and after 0, 1, 2, 3, 4, 5, 6 or 7 days an aliquot of the serum (200 µL) was cryopreserved (-80 ° C) until analyzes. Quantification of VEGF was performed using the bead array (CBA) cytometry method, used in the commercial kit (VEGF Flex Set human kit and BD™ CBA cell signaling main kit, USA), according to the manufacturer's specifications on the flow cytometer LSR Fortessa™ (BD™, USA). FCAP Array™ software version 3.0 (BD™, USA) was used to calculate the concentration of VEGF based on a curve of the pattern of this growth factor. Results were expressed in pg/mL.

#### **1.6. Statistical analyzes**

The statistical analysis used Bartlett's test for equal variances and the Kolmogorov–Smirnov test for normal distribution before comparative tests. The analyzes were performed by the paired t test or Wilcoxon to compare samples of normally or non-normally distributed data, respectively, and linear regression. The GraphPadPrism 8.0 software package (GraphPad, USA) was employed for statistical tests and graphical presentation of the data. Differences with a two-tailed value of  $p < 0.05$  were considered statistically significant.

### **3. Results**


#### **3.1. Morphological analyzes**

The qualitative analyzes represented in figure 1, showed that the PRF (Fig 1 A) is divided into three distinct regions, the upper part being formed by a fibrin network (B), the intermediate part (medium body) containing platelets immersed in the fibrin network (C) and the lower part (buffy coat) containing the largest fraction of platelets and leukocytes (D).

The platelets were intact and adhered to the fibrin network, emitting pseudopods and in degranulation, as shown in figures E, F, G, H. On the surface of the platelets were observed rough and agglomerated bodies with dimensions of  $3.0 \pm 2.0 \mu\text{m}$ . Leukocytes were closely associated with

platelets and presented a rough surface. The fibrin network exhibited variations in its three-dimensional organization, were rough and twisted, in addition to exhibiting polymeric chains with exosomatic granulations impregnated on the surface (Fig. 1 I, J).

Figures K, L, M show the PRF obtained with the SiO<sub>2</sub> platelet activator in which the planktonic diatoms frustoles are interspersed in the matrix.



**Figure 1.** Photography showing in A the macroscopy of three regions of PRF (upper body, medium body and buffy coat) and electro-micrographs (B to M). Observe the ultrastructural arrangements of the three regions of PRF (B, C, D), activated platelet (E) with pseudopods and degranulation process (F, G, H). Also, observe the fibrin surface with polymeric chains and impregnated superficial

nanoparticles (I, J). In K, L, M are shown interspersed plankton diatoms frustules in PRF matrix obtained by Vacuette™ plastic tube with a clot activator.

### 3.2. Quantification of VEGF

Our results showed an increase in the concentration of VEGF in the PRF supernatant over the 7 days of evaluation and for all g forces (200, 400 or 800 x g), with the highest concentrations observed with 200 x g, in both tubes, glass (linear regression,  $r^2 > 0.96$ ,  $p < 0.0001$ ) or plastic (linear regression,  $r^2 > 0.86$ ,  $p < 0.001$ ) (Figure 3 A, B). However, the morphometric analyzes showed a reduction in the diameter of the PRF fibers after 7 days at 37 ° C (Figure 3 C, D) and qualitatively, these analyzes indicated a decrease in the density of the fibrin network after the 7 days (Figure 3 E F G).



#### 4. Discussion

The study of fibrinolysis has two strands of high relevance. Within the vessels, this physiological process quickly prevents thromboembolism, while in the extravascular environment this process is slow because fibrin acts structurally in the injured tissue [43,44]. Considering the application of PRF in tissue repair, the elucidation of how fibrinolysis occurs in the extravascular environment can favor its therapeutic application.

For the investigation of fibrinolysis, qualitative and quantitative methods of high relevance in the clinical sphere are available to differentiate pathological conditions and indicate the appropriate therapy, which commonly involve anti-fibrinolytics such as  $\alpha_2$ -antiplasmin, a  $\alpha_2$ -macroglobulin, among others [45-49]. In this study, the objective was to understand how the fibrin network obtained with different g forces behaves as a function of time *in vitro*.

Our results showed that the variation in g-force for the production of PRF interferes with the shape of the fibrin network, as well as interfering with the release of VEGF stored within the platelets. Considering that the corpuscles containing the platelet granules were impregnated on the surface of the fibrin fibers, as shown in the images obtained by SEM, it is speculated that the lower g force applied to the blood to produce the PRF (200 x g) favored the functionality of the platelets in the release of your granules. Also, the lower g-force favored the release of VEGF from platelet granules to the PRF supernatant, culminating in the highest concentration of this growth factor and, concomitantly, in the smallest diameter of fibrin fibers observed up to 7 days. This finding may be useful in applying PRF to skin lesions, in which the rapid release of growth factors can favor the tissue repair process. Also considering that the fibrin network can be used to delivery exogenous compounds [50,51], it is possible that the use of different g-forces in the production of PRF may be related to different therapeutic applications.

It has been reported that the slow release of growth factors from the PRF is fundamental to support the therapeutic application of this platelet concentrate [52,53]. Other studies have shown that the concentration of growth factors varies according to the production protocol of PRF [54,55], mainly related to the g-force and the type of tube used.

Our results demonstrated that the use of the glass tube provided higher concentrations of VEGF released in all g-force bands, especially after 72 hours, when compared to those obtained in plastic tubes with clot activator. Bonazza et al., 2016 [29] when comparing the effects of three different types of tubes in the PRF matrix, obtained by the CGF™ method, showed a different distribution of the platelets and leukocytes and in the density of the fibrin mesh observable by immunohistochemical assays. The fibrinolysis experiment demonstrated that the concentration of growth factors increases as the fibrin fibers reduce their thickness and demonstrate detachment of particles from their surface. Thus, the lower concentration of VEGF in the exudate can have two meanings; 1) the peptide has been degraded and is not present; 2) the peptide is firmly adhered to and protected in the fibrin matrix bed.

The present experiment reproduced the immunoassay methodologies reported in the literature and served to demonstrate that PRF matrices have supraphysiological concentrations of growth factors. *In vitro* experiments are very limited since they are out under controlled environmental and metabolic conditions, unlike *in vivo* behavior.

Activated platelets and leukocytes release growth factors in the medium where they are inserted. In this way, SEM in large increases was able to demonstrate the impregnation of nanometric particles attached to fibrin fibers. Dohan, et al., 2010 [7] presented the concept of the three-dimensional model of the fibrin matrix that accommodates growth factors by adhesion. In Figure 2, we identified this configuration in a real model by SEM micrographs.

The relationship between the PRF's morphology and the VEGF release showed the interdependence of the processes. However, the released concentration, by itself, does not constitute any intrinsic advantage of the method of obtaining since the cell signaling resulting from growth factors is performed in the three-dimensional bed itself. The highest concentrations observed *in vitro* occurred precisely in the period of fibrinolysis [48]. It is also worth considering that these concentrations released from the matrix *in vitro* do not faithfully reproduce what occurs in tissue beds *in vivo*, where the action of enzymes, oxidizing agents, and migratory cells interfere with the physiological activity of these growth factors. Even because the fibrin matrix exerts a proteolytic protection mechanism on these proteins, keeping them adhered and functional for the cellular signaling that is fundamental for tissue repair [49].

Another important microscopic observation made in this study was the impregnation of different particles of silica in the PRF matrix obtained in plastic tubes with clot activators. Tubes from commercial brands presented silicon extracts from algalic sources, one of them being a composition of diatom shells. Clot activation for *in vitro* diagnostic purposes utilizes oxidizing products [56-58].

In Vitro Device (IVD), despite being sterile devices to ensure the reliability of laboratory tests is limited for medical use. According to international health standards, processed products, including blood and blood products, as well as handling devices, must have a Medical Device (MD) classification [8]. In Europe, the EU regulation 2017/745 of the European Parliament and the Council already recommends the disuse of tubes manufactured for laboratory purposes and the adoption of devices with MD classification for such purposes.

The company Silfradent in Santa Sofia, Italy, is one of the pioneers in this adaptation and already has these devices with such classification. However, despite this international sanitary adequacy, there have been no reports of cytotoxicity or therapeutic failures in the literature over the past 20 years that could be associated with the use of IVD tubes [57,59,60]. However, Tsujino et al., 2019 [58] indicated potential risks for the use of tubes containing amorphous silica as a clot activator (52), and Kawase et al., 2020 [60] demonstrated cytotoxicity in periosteal cells by contact with the silica impregnated in the tubes. There is a strong trend towards standardization for the use of tubes that are free of chemical additives.

The manufacture of plastic tubes with clot activators supplied a demand for biosafety in the field of laboratory diagnosis [61]. The glass tubes serve to accelerate the clot retraction; however, they are susceptible to breakage during handling and centrifugation, increasing the risk of accidents at work. In this way, the use of plastic tubes with clot activators, in laboratory logistics, accelerate the formation of the clot and reduce the risks of these accidents<sup>4</sup>.

Bowen and Remaley, 2014 [62] clarified that laboratory analytical methods are susceptible to variations in additives used in the manufacture of tubes for *in vitro* diagnostics, thus interfering with the results of the analyzes. Contaminating agents such as lead and other heavy metals present in the rubbers and lubricants used to close the tubes can affect the accuracy of laboratory tests.

Some companies involved in the sale of centrifuges and supplies for obtaining blood concentrates, in compliance with international health regulations, already have in their sterile portfolio tubes in specific packages with the indicative description for *in vivo* use<sup>28</sup>.

Despite this international health trend regarding the indication of equipment and supplies classified as a medical device (MD), there is no indication in the international literature of inefficiency, toxic or immunogenic implications due to the use of IVD tubes containing clot activators in obtaining PRF matrices.

The glass tube due to the better kinetic pattern presented in the slow release of VEGF observed in the present study can be indicated for obtaining the PRF matrices for non-transfusion therapeutic use. Studies using experimental models *in vivo* and *in vitro* are necessary to clarify the cytotoxic potential of these activators or inactivity *in locus*.

## 5. Conclusions

The microscopic and flow cytometric experiments showed the effect of the different experimental conditions, where the smallest g-forces were more promising concerning cell composition and VEGF release. Our results showed that g-force interferes with the shape of the fibrin network in the PRF, as well as affect the release of VEGF stored into platelets. This finding may be useful in applying PRF to skin lesions, in which the rapid release of growth factors can favor the tissue repair process. Our observations point to a greater clarification on the methodological variations related to obtaining PRF matrices, as they can generate products with characteristics and different degrees of effectiveness in specific applications.

**Author Contributions:** conceptualization, LAO and SASK.; methodology, LAO and TKB; formal analysis, LAO and SASK; investigation, LAO and TKB.; resources, LAO and MB; data curation, SASK.; writing—original draft preparation, LAO; writing—review and editing, LAO and ROS.; visualization, LAO; supervision, MB and SASK.; project administration, LAO.

**Acknowledgments:** We are grateful to technical staffs Biology Institute's microscopy and microanalysis laboratory - University of Brasilia for supporting.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Mosesson, M.W. Fibrinogen and fibrin structure and functions. *J Thromb Haemost* **2005**, *3*, 1894–1904.
2. Weisel, J.W.; Litvinov, R.I. Mechanisms of fibrin polymerization and clinical implications. *Blood* **2013**, *121*, 1712–1719.
3. Kononova, O.; Litvinov, R.I.; Zhmurov, A.; Alekseenko, A. Cheng, C.H.; Agarwal, S.; Marx, K.A.; Weisel, J.W.; Barsegov, V. Molecular mechanisms, thermodynamics, and dissociation kinetics of knob-hole interactions in fibrin. *J Biol Chem* **2013**, *288*, 22681–22692. [PubMed]
4. Yavas, S.; Ayaz, S.; Köse, S. K.; Ulus, F.; Ulus, A. T. Influence of Blood Collection Systems on Coagulation Tests. *Turk J Hematol* **2012**, *29*, 367–375.
5. Dohan Ehrenfest, D. M.; Andia, I.; Zumstein, M.A.; Zhang, CQ.; Pinto, N.R.; Bieleki, T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. *Muscles, Ligaments and Tendons Journal* **2014**, *3*, 0–3.
6. Choukroun, J.; Diss, A.; Simonpieri, A.; Girard, M.O.; Schoeffler, C.; Dohan, S.L.; Dohanm A.J.J.; Mouhyi, J.; Dohan Ehrenfest, D. M. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part IV: Clinical effects on tissue healing *OOOOE* **2006**, *101*, E56–E60.
7. Dohan Ehrenfest, D.M.; Del Corso, M.; Diss, A.; Mouhyi, J.; Charrier, J.B. Three-dimensional architecture and cell composition of a Choukroun's platelet-rich fibrin clot and membrane. *Journal of periodology* **2012**, *81*, 546–555.
8. Miron, R.; Choukroun, J.; Ghanaati, S. Controversies Related to Scientific Report Describing G-Forces from Studies on Platelet-Rich Fibrin: Necessity for Standardization of Relative Centrifugal Force Values. *Int J Growth Factors Stem Cells Dent* **2018**, *1*, 80–89.
9. Kubesch, A.; Barbeck, M.; Al-Maawi, S.; Orłowska, A.; Booms, P.F.; Sader, R.A.; Miron, R.J.; Kirkpatrick, C.J.; Choukroun, J.; Ghanaati, S. Controversies Related to Scientific Report Describing G-Forces from Studies on Platelet-Rich Fibrin: Necessity for Standardization of Relative Centrifugal Force Values. *Platelets* **2019**, *1*, 329–340.
10. Mariani, E.; Pulsatelli, L.P. Platelet concentrates in musculoskeletal medicine. *Int J Mol Sci* **2020**, *21*, 1–43.
11. Miron, R.J.; Fujioka-Kobayashi, M.; Kandalam, U.; Zhang, Y.; Ghanaati, S.; Choukroun, J. Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry?. *Clinical oral investigations* **2017**, *21*, 2619–2627.

12. Chiaravalloti, A.J.; Zubkov, B.; Zubkov, A. Treatment of a Chronic Cutaneous Surgical Wound with Platelet-Rich Fibrin. *Am Soc Dermatologic Sur* **2018**, *44*, 449–452.
13. Geaney, L.E.; Arciero, R.A.; DeBerardino, T.M.; Mazzocca, A.D. The Effects of Platelet-Rich Plasma on Tendon and Ligament: Basic Science and Clinical Application. *Oper Tech Sports Med* **2011**, *19*, 160–164.
14. Rodeo, S.A. Biologic augmentation of rotator cuff tendon repair. *J Shoulder Elbow Surg.* **2007**, *16*, S191–S197.
15. ElShourbagy, M.H.; Hussein, M.M.; Khedr, M.S; Abd Elal, S. Oroantral communication repair using bone substitute and platelets rich fibrin. *Tanta Dent J* **2015**, *12*, 65–S70.
16. Wallace, S.S. Tarnow, D.P.; Froum, S.J.; Cho, S.C; Zadeh, H.H.; Stoupel, J.; Del Fabbro, M.; Testori, T. Maxillary Sinus Elevation by Lateral Window Approach: Evolution of Technology and Technique. *J Evid Based Dent Pract* **2012**, *12*, 161–171.
17. Zhang, Y.; Tangl, S.; Huber, C.D.; Lin, Y.; Qiu, L.; Rausch-Fan, X. Effects of Choukroun's platelet-rich fibrin on bone regeneration in combination with deproteinized bovine bone mineral in maxillary sinus augmentation: A histological and histomorphometric study. *J Cranio-Maxillofacial Surg* **2012**, *40*, 321–328.
18. Soydan, S.S.; Uckan, S. Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: Technical report. *J Oral Maxillofac Surg* **2014**, *72*, 322–326.
19. Henry, P.; Wasserstein, D.; Park, S.; Dwyer, T.; Chahal, J.; Slobogean, G.; Schemitsch, E. Arthroscopic Repair for Chronic Massive Rotator Cuff Tears: A Systematic Review. *Arthrosc J Arthrosc Rela Surg* **2015**, *31*, 2472–2480.
20. Giannini, S.; Buda, R.; Cavallo, M.; Ruffilli, A.; Cenacchi, A.; Cavallo, C.; Vannini, F. Cartilage repair evolution in post-traumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bone-marrow-derived cells transplantation. *Injury* **2010**, *41*, 196–203.
21. Zumstein, M. A.; Bielecki, T.; Dohan Ehrenfest, D. M. The Future of Platelet Concentrates in Sports Medicine: Platelet-Rich Plasma, Platelet-Rich Fibrin, and the Impact of Scaffolds and Cells on the Long-term Delivery of Growth Factors. *J Oper Tech Sports Med* **2011**, *19*, 190–197.
22. Dohan, S.; Choukroun, J.; Dohan, A.; Donsimoni, J.M.; Gabrieleff, D.; Fioretti, F.; Dohan, D. Platelet Rich Fibrin (PRF) : un nouveau biomatériau de cicatrisation: Biotechnologies et fibrine, plaquettes et cytokines, aspects immunitaires, implications thérapeutiques. 1re partie: biotechnologies et fibrine Platelet Rich Fibrin (PRF): a new healing biomaterial: 1st part: biotechnologies and fibrin. *Implantodontie* **2004**, *13*, 87–97.
23. Ibilgia, J.B.; Vizcaíno, C.H.; Weisleder, H.; Choukroun, J.; Ghanaati, S. Liquid platelet-rich fibrin injections as a treatment adjunct for painful temporomandibular joints: preliminary results. *Cranio - J Craniomandib Pract* **2018**, *20*, 1–13.
24. Choukroun, J.; Ghanaati, S. Reduction of relative centrifugation force within PRF- (Platelet-Rich-Fibrin) concentrates advances patients' own inflammatory cells and platelets: First introduction of the Low Speed Centrifugation Concept. *ETOJ* **2018**, *44*, 87–95.
25. Pinto, N.R.; Ubilla, M.; Zamora, Y.; Rio, V.; Ehrenfest Dohan, M.D.; Quirynen, M. Leucocyte-and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study. *Platelets* **2018**, *29*, 468–475.
26. Ehrenfest Dohan, D.M.; Pinto, N.R.; Pereda, A.; Jiménez, P.; Del Corso, M.; Kang, B.S.; Nally, M.; Lanata, N.; Wang, H.L.; Quirynen, M. (2017) Platelets Ehrenfest Dohan, D.M.; Pinto, N.R.; Pereda, A.; Jiménez, P.; Del Corso, M.; Kang, B.S.; Nally, M.; Lanata, N.; Wang, H.L.; Quirynen, M. The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte- and platelet-rich fibrin (L-PRF) clot and membrane. *Platelets* **2017**, *00*, 1369–1635.
27. Rodella, L.F.; Favero, G.; Boninsegna, R.; Buffoli, B.; Labanca, M.; Scari, G.; Sacco, L.; Batani, T.; Rezzani, R. Growth factors, CD34 positive cells, and fibrin network analysis in concentrated growth factors fraction. *Microsc Res Tech* **2011**, *74*, 772–777.
28. Borsani, E.; Bonazza, V.; Buffoli, B.; Cocchi, M.A.; Castrezzati, S.; Scari, G.; Baldi, F.; Pandini, S.; Licenziati, S.; Parolini, S.; Rezzani, R.; Rodella, L.F. Biological Characterization and In Vitro Effects of Human Concentrated Growth Factor Preparation: An Innovative Approach to Tissue Regeneration. *Biology and Medicine* **2015**, *7*, 1–11.
29. Bonazza, V.; Borsani, E.; Buffoli, B.; Castrezzati, S.; Rezzani, R.; Rodella, L.F. How the different material and shape of the blood collection tube influences the Concentrated Growth Factors production. *Microsc Res Tech* **2016**, *00*, 1–6.

30. Dong-Seok Sohn, B.H.; Jin Kim, W.; Eric Park, C.C.P. Utilization of Autologous Concentrated Growth Factors (CGF) Enriched Bone Graft Matrix (Sticky Bone) and CGF-Enriched Fibrin Membrane in Implant Dentistry. *J Implant Adv* **2015**, *7*, 17–29.
31. Anitua, E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. *Int J Oral Maxillofac Implants* **1999**, *volume*, 529–535.
32. Anitua, E.; Sánchez, M.; Nurden, A.T.; Nurden, P.; Orive, G.; Andía, I. New insights into and novel applications for platelet-rich fibrin therapies. *Trends in Biotechnology* **2006**, *24*, 227–234.
33. Oliveira, L.A.; Buzzi, M.; Leão, M.P.; Andrade, P.C.A.R.; Kuckelhaus, S.A.S. Ultrastructural morphological characterization of the autologous leuko-platelet fibrin matrix in association with xenogenic and alloplastic biomaterials for bone grafting. *Fibrin Protocol. Rev Catar Implantodont* **2018**, *18*, 24–33.
34. Arabaci, T.; Albayrak, M. Titanium-Prepared platelet rich fibrin provides advantages on periodontal healing: A randomized split mouth clinical study.. *J Periodontol* **2018**, *89*, 255–264.
35. Lourenço, E.S.; Mourão, C.F.A.B.; Leite, P.E.C.; Granjeiro, J.M.; Calasans-Maia, M.D.; Alves, G.G. The in vitro release of cytokines and growth factors from fibrin membranes produced through horizontal centrifugation. *J Biomed Mater Res Part A* **2018**, *106*, 1373–1380.
36. Miron, R.J.; Chai, J.; Zheng, S.; Feng, M.; Sculean, A.; Zhang, Y. Título. *J Biomed Mater Res Part A* **2019**, *107*, 2257–2271.
37. Liu, Z.; Jin, H.; Xie, Q.; Jiang, Z.; Guo, S.; Li, S.; Zhang, B. Controlled Release Strategies for the Combination of Fresh and Lyophilized Platelet-Rich Fibrin on Bone Tissue Regeneration. *Biomed Res Int* **2019**, *00*, 1–10.
38. Mourão, C.F.; Valiense, H.; Melo, E.R.; Mourão, N.B.; Calasans-Maia, M.D. Obtention of injectable platelets rich-fibrin (i-PRF) and its polymerization with bone graft: technical note. *Rev Col Bras Cir* **2015**, *42*, 421–423.
39. Kobayashi, M.; Kawase, T.; Horimizu, M.; Okuda, K.; Wolff, L.F.; Yoshie, H. A proposed protocol for the standardized preparation of PRF membranes for clinical use. *Biologicals* **2012**, *40*, 323–329.
40. Khorshidi, H.; Raoofi, S.; Bagheri, R.; Banihashemi, H. Comparison of the Mechanical Properties of Early Leukocyte- and Platelet-Rich Fibrin versus PRGF / Endoret Membranes. *Hindawi Publ Corp* **2016**, *00*, 1–7.
41. Pretorius, E.; Vieira, W. A.; Oberholzer, H. M.; Auer, R. E. J. Comparative Scanning Electron Microscopy of Platelets and Fibrin Networks of Human and Different Animals. *Int J Morphol* **2009**, *27*, 69–76.
42. Kim, T.H.; Kim, S.H.; Sándor, G.K.; Kim, Y.D. Comparison of platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and concentrated growth factor (CGF) in rabbit-skull defect healing. *Arch Oral Biol* **2014**, *59*, 550–558.
43. Gersh, K.C.; Nagaswami, C.; Weisel, J.W. Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes. *Thromb Haemost* **2009**, *102*, 1169–1175.
44. Bannish, B.E.; Keener, J.P.; Woodbury, M.; Weisel, J.W.; Fogelson, A.L. Modelling fibrinolysis: 1D continuum models. *Math Med Biol* **2014**, *31*, 45–64.
45. Longstaff, C. Measuring fibrinolysis: from research to routine diagnostic assays. *J Thromb Haemost* **2018**, *16*, 652–662.
46. Ilich, A.; Bokarev, I.; Key, N.S. Global assays of fibrinolysis. *Int J Lab Hematol* **2017**, *39*, 441–447.
47. Whyte, C.S.; Mitchell, J.L.; Mutch, N.J. Platelet-Mediated Modulation of Fibrinolysis. *Semin Thromb Hemost* **2017**, *43*, 115–128.
48. Wehner, C.; Janjic, K.; Agis, H. Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties. *Arch Oral Biol* **2016**, *74*, 136–145.
49. Zubairova, L.D.; Nabiullina, R.M.; Nagaswami, C.; Zuev, Y.F.; Mustafin, I.G. Litvinov, R.I.; Weisel, J.W. Circulating Microparticles Alter Formation, Structure, and Properties of Fibrin Clots. *Sci Rep* **2015**, *5*, 1–13.
50. Ahmad, E.; Fatima, M.T.; Hoque, M.; Owais, M.; Saleemuddin, M. Fibrin matrices: The versatile therapeutic delivery systems. *Int J Biol Macromol* **2015**, *81*, 121–136.
51. Polak, D.; Clemer-Shamai, N.; Shapira, L. Incorporating antibiotics into platelet-rich fibrin: A novel antibiotics slow-release biological device. *J Clin Periodontol.* **2019**, *46*, 241-247.
52. Ratajczak, J.; Vanganswinkel, T.; Gervois, P.; Merckx, G.; Hilkens, P.; Quirynen, M.; Lambrichts, I.; Bronckaers, A. Angiogenic Properties of ‘Leukocyte- and Platelet-Rich Fibrin’. *Sci Rep* **2018**, *8*, 1-10.
53. Tohidnezhad, M.; Wruck, C.J.; Slowik, A.; Kweider, N.; Beckmann, R.; Bayer, A.; Houben, A.; Brandenburg, L.O.; Varoga, D.; Sönmez, T.T.; Stoffel, M.; Jahr, H.; Lippross, S.; Pufe, T. Role of platelet-released growth factors in detoxification of reactive oxygen species in osteoblasts. *Bone* **2014**, *65*, 9–17.

54. Su, C.Y.; Kuo, Y.P.; Tseng, Y.H.; Su, C.H.; Burnouf, T. In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF. *OOOOE* **2009**, *108*, 56-61.
55. Giannini, S.; Cielo, A.; Bonanome, L.; Rastelli, C.; Derla, C.; Corpaci, F.; Falisi, G. Comparison between PRP, PRGF and PRF: lights and shadows in three similar but different protocols. *Eur Rev Med Pharmacol Sci* **2015**, *19*, 927-30.
56. Lippi, G.; Cornes, M.P.; Grankvist, K.; Nybo, M.; Simundic, A.M. EFLM WG-Preanalytical phase opinion paper: local validation of blood collection tubes in clinical laboratories. *Clin Chem Lab Med* **2016**, *5*, 755-60.
57. Corbalan, J.; Medina, C.; Jacoby, A.; Malinski, T.; Radomski, M.W. Amorphous silica nanoparticles aggregate human platelets: Potential implications for vascular homeostasis. *Int J Nanomedicine* **2012**, *7*, 631-639.
58. Tsujino, T.; Takahashi, A.; Yamaguchi, S.; Watanabe, T. Evidence for Contamination of Silica Microparticles in Advanced Platelet-Rich Fibrin Matrices Prepared Using Silica-Coated Plastic Tubes. *Biomedicines* **2019**, *7*, 1-11.
59. Dohan Ehrenfest, D.M.; Diss, A.; Odin, G.; Doglioli, P.; Hippolyte, M.P.; Charrier, J.B. In vitro effects of Choukroun's PRF (platelet-rich fibrin) on human gingival fibroblasts, dermal prekeratinocytes, preadipocytes, and maxillo facial osteoblasts in primary cultures. *OOOOE* **2009**, *108*, 341-352.
60. O'Connell, S. M. Safety Issues Associated with Platelet-Rich Fibrin Method. *OOOOE* **2007**, *103*, 587-593.
61. Masuki, H.; Isobe, K.; Kawabata, H.; Tsujino, T.; Yamaguchi, S.; Watanabe, T.; Sato, A.; Aizawa, H.; Mourão, C.F.B.; Kawase, T. Acute cytotoxic effects of silica microparticles used for coating of plastic blood-collection tubes on human periosteal cells. *Odontology* **2020**, *00*, 1-8.
62. Bowen, R.A.R.; Remaley, A.T. Interferences from blood collection tube components on clinical chemistry assays. *Biochem Medica* **2014**, *24*, 31-44.